< Back to previous page
Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerFrom1 Apr 2020 → 21 May 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 105
- GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer(2025)Published in: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCERISSN: 1048-891XIssue: 11Volume: 35
- Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study.(2025)Published in: BrachytherapyISSN: 1538-4721Pages: S1538-4721
- Presence of atypical extravillous trophoblast foci is an independent predictor of the risk of progression to postmolar neoplasia(2025)Published in: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGYISSN: 0002-9378Issue: 4Volume: 233
- Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.(2025)Published in: JOURNAL OF CLINICAL ONCOLOGYISSN: 0732-183XIssue: 26Volume: 43Pages: 2908 - 2917
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201(2025)Published in: JOURNAL OF CLINICAL ONCOLOGYISSN: 0732-183XIssue: 25Volume: 43
- GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53 consortium.(2025)Published in: CLINICAL CANCER RESEARCHISSN: 1078-0432Issue: 15Volume: 31
- Single-cell profiling in ovarian germ cell and sex cord-stromal tumours(2025)Published in: British Journal of CancerISSN: 0007-0920Issue: 12Volume: 132Pages: 1110 - 1123
- Exploring the heterogeneity of rare ovarian cancer(2025)
- Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)(2025)Published in: Journal of Gynecologic OncologyISSN: 2005-0380Issue: 1Volume: 36
- Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study(2024)Published in: GYNECOLOGIC ONCOLOGYISSN: 0090-8258Volume: 191Pages: 172 - 181